Selection and analysis of an optimized Anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen

Journal of Molecular Biology

Volumn 293, Issue 4, 1999, Pages 865-881

  Chen, Yvonne ^a   Wiesmann, Christian ^a   Fuh, Germaine ^a   Li, Bing ^a   Christinger, Hans W ^a   McKay, Patrick ^a   De Vos, Abraham M ^a   Lowman, Henry B ^a  

^a GENENTECH INC   (United States)

Author keywords

Affinity maturation; Angiogenesis; Humanized antibody antigen complex; Phage display; X ray crystallography

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MUTANT PROTEIN; VASCULOTROPIN;

ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HYDROGEN BOND; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

EID: 0033527584     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.3192     Document Type: Article

References (48)

1. Baca M., Presta L. G., O'Connor S. J., Wells J. A. Antibody humanization using monovalent phage display. J. Biol. Chem. 272:1997;10678-10684.
2. Barbas C. F. III, Hu D., Dunlop N., Sawyer L., Cababa D., Hendry R. M., Nara P. L., Burton D. R. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc. Natl Acad. Sci. USA. 91:1994;3809-3813.
3. Bass S., Greene R., Wells J. A. Hormone phage: an enrichment method for variant proteins with altered binding properties. Proteins: Struct. Funct. Genet. 8:1990;309-314.
4. Brünger A. T., Kuriyan J., Karplus M. Crystallographic R factor refinement by molecular dynamics. Science. 235:1987;458-460.
5. CCP4. Programs for protein crystallography. Acta Crystallog. sect. D. 50:1994;760-763.
6. Chothia C., Lesk A. M. Canonical structures for the hypervariable reigions of immunoglobulins. J. Mol. Biol. 196:1987;901-917.
7. Delisi C. Role of diffusion regulation in receptor-ligand interactions. Methods Enzymol. 93:1983;95-109.
8. Fairbrother W. J., Christinger H. W., Cochran A. G., Fuh G., Keenan C. J., Quan C., Shriver S. K., Tom J. Y., Wells J. A., Cunningham B. C. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry. 37:1998;17754-17764.
9. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36:1995;127-137.
10. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237:1999;1-30.
11. Ferrara N., Henzel W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:1989;851-858.
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:1995;27-31.
13. Folkman J., Klagsbrun M. Angiogenic factors. Science. 235:1987;442-443.
14. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224:1992;487-499.
15. Gitay-Goren H., Soker S., Vlodavsky I., Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell-surface-associated heparin-like molecules. J. Biol. Chem. 267:1992;6093-6098.
16. Griffiths A. D., Duncan A. R. Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 9:1998;102-108.
17. Hawkins R. E., Russell S. J., Winter G. Selection of phage antibodies by binding affinity mimicking affinity maturation. J. Mol. Biol. 226:1992;889-896.
18. Hawkins R. E., Russell S. J., Baier M., Winter G. The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. J. Mol. Biol. 234:1993;958-964.
19. Iruela-Arispe M. L., Dvorak H. F. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb. Haem. 78:1997;672-677.
20. Jones T. A., Zhou J.-Y., Cowan S. W., Kjelgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A. 47:1991;110-119.
21. Kabat E. A., Wu T. T., Redi-Miller M., Perry H. M., Gottesman K. S. Sequences of Proteins of Immunological Interest. 1987;National Institutes of Health, Bethesda.
22. Karlsson R., Michaelsson A., Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J. Immunol. Methods. 145:1991;229-240.
23. Kay B. K., Hoess R. H. Principles and applications of phage display. Kay B. K., Winter J., McCafferty J. Phage Display of Peptides and Proteins. 1996;21-34 Academic Press, San Diego.
24. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
25. Kraft A., Weindel K., Ochs A., Marth C., Zmija J., Schumacher P., Unger C., Marmé D., Gastl G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 85:1999;178-187.
26. Kunkel T. A., Bebenek K., McClary J. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 204:1991;125-139.
27. Küttner G., Keitel T., Gießmann E., Wessner H., Scholz C., Höhne W. A phage library-derived single-chain Fv fragment in complex with turkey egg-white lysozyme: characterization, crystallization and preliminary X-ray analysis. Mol. Immunol. 35:1998;189-194.
28. Laskowski R. A., MacArthur M. W., Moss D. S., Thornton J. M. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;283-291.
29. Lowman H. B. Phage display of peptide libraries on protein scaffolds. Cabilly S. Methods in Molecular Biology, Combinatorial Peptide Library Protocols. 1998;249-264 Humana Press, Totowa.
30. Lowman H. B., Wells J. A. Affinity maturation of human growth hormone by monovalent phage display. J. Mol. Biol. 234:1993;564-578.
31. Lowman H. B., Bass S. H., Simpson N., Wells J. A. Selecting high-affinity binding proteins by monovalent phage display. Biochemistry. 30:1991;10832-10838.
32. Malmborg A.-C., Michaelsson A., Ohlin M., Jansson B., Borrebaeck C. A. K. Real time analysis of antibody-antigen reaction kinetics. Scan. J. Immunol. 35:1992;643-650.
33. Marks J. D., Griffiths A. D., Malmqvist M., Clackson T. P., Bye J. M., Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology. 10:1992;779-783.
34. Mordenti J., Thomsen K., Licko V., Chen H., Meng Y. G., Ferrara N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol. Pathol. 27:1999;14-21.
35. Muller Y. A., Li B., Christinger H. W., Wells J. A., Cunningham B. C., de Vos A. M. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl Acad. Sci. USA. 94:1997;7192-7197.
36. Muller Y. A., Chen Y., Christinger H. W., Li B., Cunningham B. C., Lowman H. B., de Vos A. M. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 Å resolution and mutational analysis of the interface. Structure. 6:1998a;1153-1167.
37. Muller Y. A., Christinger H. W., Keyt B. A., de Vos A. M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding. Structure. 5:1998b;1325-1338.
38. Munson P., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107:1980;220-239.
39. Nezlin R. The Immunoglobulins: Structure and Function. 1998;Academic Press, San Diego. p. 151-204.
40. Presta L. G., Chen H., O'Connor S. J., Chisholm V., Meng Y. G., Krummen L., Winkler M., Ferrara N. Humanization of a vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 47:1997;4593-4599.
41. Rader C., Barbas C. F. III. Phage display of combinatorial antibody libraries. Curr. Opin. Biotechnol. 8:1997;503-508.
42. Schier R., McCall A., Adams G. P., Marshall K. W., Merritt H., Yim M., Crawford R. S., Weiner L. M., Marks C., Marks J. D. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263:1996;551-567.
43. Thompson J., Pope T., Tung J.-S., Chan C., Hollis G., Mark G., Johnson K. S. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J. Mol. Biol. 16:1996;77-88.
44. Tramontano A., Chothia C., Lesk A. M. Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J. Mol. Biol. 215:1990;175-182.
45. Wells J. A. Additivity of mutational effects in proteins. Biochemistry. 29:1990;8509-8517.
46. 3-specific humanized mAb. Proc. Natl Acad. Sci. USA. 95:1998;6037-6042.
47. Xiang J., Sha Y., Jia Z., Prasad L., Delbaere L. T. Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of heavy-chain hypervariable loops. J. Mol. Biol. 253:1995;385-390.
48. Yang W.-P., Green K., Pinz-Sweeney S., Briones A. T., Burton D. R., Barbas C. F. III. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254:1995;392-403.